Despite market uncertainty, healthcare CEOs of all stripes remain upbeat about 2019
| MedCity News

The market gyrations and the shutdown. The trade wars and global uncertainty. None of the above has squashed the sunny optimism that a group of healthcare CEOs demonstrated at a roundtable discussion during the annual J.P. Morgan Healthcare Conference in San Francisco last week.

United Neuroscience To Move Forward Alzheimer’s Vaccine After Promising Phase IIa
| Scrip

Private, Dublin-based biotech United Neuroscience says it plans to rapidly advance its active Alzheimer’s vaccine immunotherapy UB-311 after reporting positive top-line results from a Phase IIa study of 42 patients on Jan. 16. The company’s lead candidate UB-311 is a novel synthetic peptide that targets beta amyloid in Alzheimer’s disease, with the goal of preventing and treating […]

United Neuro seeks ‘cautiously optimistic’ next step with AD vaccine candidate
| BioWorld

United Neuroscience Ltd. posted top-line results from a phase IIa study of UB-311, its synthetic peptide vaccine candidate targeting beta-amyloid (A-beta) for the treatment of Alzheimer’s disease (AD), showing the effort met the primary aims of safety and immunogenicity with a 96 percent response rate. Secondary endpoints, which included amyloid PET burden as well as scores from […]